According to Baiyang Pharmaceutical's announcement, the company recently received a letter from the controlling shareholder Baiyang Pharmaceutical Group Co., Ltd. to learn that its 6,771,768 shares of the company have been released from the pledge, accounting for 1.92% of the company's total share capital and 1.29% of the shares it holds. The pledge holder is Daye Trust Co., Ltd. As of the disclosure date of the announcement, the controlling shareholders and their co-actors held a total of 390,957,310 shares of the company, accounting for 74.38% of the total share capital; they pledged a cumulative total of 185,220,613 shares, accounting for 47.38% of their shares and 35.24% of the company's total share capital. The shares held were not frozen or auctioned, and there was no risk of closing the pledged shares.

According to Baiyang Pharmaceutical's announcement, the company recently received a letter from the controlling shareholder Baiyang Pharmaceutical Group Co., Ltd. to learn that its 6,771,768 shares of the company have been released from the pledge, accounting for 1.92% of the company's total share capital and 1.29% of the shares it holds. The pledge holder is Daye Trust Co., Ltd. As of the disclosure date of the announcement, the controlling shareholders and their co-actors held a total of 390,957,310 shares of the company, accounting for 74.38% of the total share capital; they pledged a cumulative total of 185,220,613 shares, accounting for 47.38% of their shares and 35.24% of the company's total share capital. The shares held were not frozen or auctioned, and there was no risk of closing the pledged shares.